/
/
/

Gennex Laboratories Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-20%31%59%
-58%64%38%
-9%14%3%
8%10%10%10%

Peer Comparison

Symbol
SUNPHARMA-A
DIVISLAB-A
TORNTPHARM-A
ZYDUSLIFE-A
CIPLA-A
LAURUSLABS-A
LUPIN-A
MANKIND-A
DRREDDY-A
AUROPHARMA-A
GENNEX-X
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,899.85₹456833 Cr37.7712.0762.82₹11479 Cr
9,137₹245426 Cr83.9134.04128.41₹2568 Cr
4,837.35₹187320 Cr85.8916.7297.06₹2163 Cr
1,130.4₹113217 Cr25.099.4262.53₹5040 Cr
1,380.6₹112212 Cr33.299.7757.87₹3879 Cr
1,843.8₹101155 Cr92.526.829.25₹889 Cr
2,109.55₹97626 Cr17.6630.95154.36₹5333 Cr
2,331.35₹96859 Cr47.4213.7571.08₹1913 Cr
1,157₹96406 Cr29.925.3263.99₹4196 Cr
1,653.55₹93614 Cr25.2217.9596.84₹3505 Cr
12₹287 Cr14.780.190.91₹21 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Dec 2021Sep 2021Jun 2021Dec 2020Sep 2020Jun 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Dec 2017Sep 2017
₹40 Cr₹61 Cr₹43 Cr₹39 Cr₹34 Cr₹40 Cr₹40 Cr₹33 Cr₹28 Cr₹34 Cr₹21 Cr₹18 Cr₹16 Cr₹19 Cr₹15 Cr₹20 Cr₹14 Cr₹17 Cr₹14 Cr₹10 Cr₹16 Cr₹15 Cr₹13 Cr₹15 Cr₹14 Cr₹16 Cr₹20 Cr₹15 Cr₹11 Cr₹9 Cr₹12 Cr₹10 Cr
₹2 Cr₹1 Cr₹0₹0₹2 Cr₹4 Cr₹0₹0₹2 Cr₹2 Cr₹0₹0₹3 L₹2 Cr₹0₹0₹57 L₹0₹0₹3 L₹0₹0₹15 L₹0₹0₹34 L₹25 L₹0₹0₹14 L₹0₹3 L
₹42 Cr₹62 Cr₹43 Cr₹39 Cr₹36 Cr₹44 Cr₹40 Cr₹33 Cr₹31 Cr₹36 Cr₹21 Cr₹18 Cr₹17 Cr₹21 Cr₹15 Cr₹20 Cr₹15 Cr₹17 Cr₹14 Cr₹10 Cr₹16 Cr₹15 Cr₹13 Cr₹15 Cr₹14 Cr₹16 Cr₹21 Cr₹15 Cr₹11 Cr₹10 Cr₹12 Cr₹11 Cr
₹36 Cr₹56 Cr₹35 Cr₹32 Cr₹30 Cr₹39 Cr₹33 Cr₹26 Cr₹25 Cr₹29 Cr₹17 Cr₹13 Cr₹12 Cr₹18 Cr₹13 Cr₹18 Cr₹13 Cr₹16 Cr₹13 Cr₹9 Cr₹14 Cr₹14 Cr₹13 Cr₹14 Cr₹13 Cr₹15 Cr₹19 Cr₹14 Cr₹10 Cr₹9 Cr₹11 Cr₹10 Cr
₹6 Cr₹7 Cr₹9 Cr₹8 Cr₹7 Cr₹6 Cr₹7 Cr₹7 Cr₹7 Cr₹6 Cr₹5 Cr₹6 Cr₹5 Cr₹4 Cr₹2 Cr₹2 Cr₹1 Cr₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹89 L₹81 L₹1 Cr₹2 Cr₹2 Cr₹1 Cr₹89 L₹88 L₹94 L₹81 L
₹90 L₹1 Cr₹1 Cr₹1 Cr₹98 L₹1 Cr₹84 L₹1 Cr₹73 L₹73 L₹83 L₹78 L₹73 L₹63 L₹18 L₹36 L₹26 L₹14 L₹24 L₹15 L₹14 L₹23 L₹16 L₹17 L₹18 L₹23 L₹20 L₹26 L₹17 L₹17 L₹15 L₹20 L
₹5 Cr₹5 Cr₹7 Cr₹6 Cr₹6 Cr₹4 Cr₹6 Cr₹6 Cr₹6 Cr₹5 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹2 Cr₹1 Cr₹2 Cr₹1 Cr₹51 L₹34 L₹75 L₹1 Cr₹1 Cr₹82 L₹48 L₹47 L₹51 L₹40 L
₹5 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹3 Cr₹5 Cr₹5 Cr₹5 Cr₹4 Cr₹3 Cr₹3 Cr₹3 Cr₹2 Cr₹1 Cr₹1 Cr₹75 L₹79 L₹1 Cr₹95 L₹1 Cr₹87 L₹37 L₹20 L₹56 L₹80 L₹45 L₹82 L₹48 L₹47 L₹31 L₹40 L

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
₹23 Cr₹23 Cr₹18 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr₹13 Cr
₹6 Cr₹6 Cr₹0₹0₹0₹0₹0₹0₹0
₹158 Cr₹142 Cr₹62 Cr₹31 Cr₹27 Cr₹23 Cr₹21 Cr₹19 Cr₹18 Cr
₹158 Cr₹142 Cr₹62 Cr₹31 Cr₹27 Cr₹23 Cr₹21 Cr₹19 Cr₹18 Cr
₹187 Cr₹170 Cr₹80 Cr₹44 Cr₹40 Cr₹36 Cr₹34 Cr₹32 Cr₹31 Cr
₹8 Cr₹6 Cr₹6 Cr₹0₹0₹0₹0₹0₹0
₹14 Cr₹13 Cr₹16 Cr₹0₹0₹0₹0₹35 L₹9 L
₹0₹0₹0₹0₹0₹0₹0₹8 L₹10 L
-₹18 L-₹23 L-₹14 L₹32,429₹15 L₹40 L₹56 L₹61 L₹95 L
₹3 Cr₹0₹0₹0₹2 L₹2 L₹5 L₹0₹0
₹17 Cr₹13 Cr₹16 Cr₹32,429₹17 L₹41 L₹62 L₹1 Cr₹1 Cr
₹13 Cr₹15 Cr₹7 Cr₹8 Cr₹6 Cr₹8 Cr₹8 Cr₹12 Cr₹9 Cr
₹13 Cr₹14 Cr₹17 Cr₹4 Cr₹3 Cr₹5 Cr₹3 Cr₹3 Cr₹3 Cr
₹10 Cr₹6 Cr₹1 Cr₹10 Cr₹7 Cr₹5 Cr₹5 Cr₹2 Cr₹4 Cr
₹8 Cr₹6 Cr₹4 Cr₹3 Cr₹2 Cr₹2 Cr₹1 Cr₹45 L₹50 L
₹45 Cr₹40 Cr₹30 Cr₹24 Cr₹19 Cr₹21 Cr₹17 Cr₹18 Cr₹17 Cr
₹256 Cr₹230 Cr₹132 Cr₹68 Cr₹59 Cr₹57 Cr₹52 Cr₹50 Cr₹49 Cr
₹98 L₹98 L₹74 L₹74 L₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr
₹24 Cr₹19 Cr₹17 Cr₹10 Cr₹7 Cr₹5 Cr₹5 Cr₹3 Cr₹4 Cr
₹82 Cr₹76 Cr₹92 Cr₹31 Cr₹30 Cr₹30 Cr₹30 Cr₹29 Cr₹28 Cr
₹23 Cr₹21 Cr₹18 Cr₹17 Cr₹16 Cr₹15 Cr₹14 Cr₹13 Cr₹12 Cr
₹60 Cr₹56 Cr₹74 Cr₹14 Cr₹14 Cr₹15 Cr₹16 Cr₹16 Cr₹16 Cr
₹5 Cr₹2 Cr₹2 L₹0₹0₹0₹0₹0₹23 L
₹1 L₹1 L₹1 L₹7 Cr₹7 Cr₹7 Cr₹7 Cr₹7 Cr₹7 Cr
₹1 L₹1 L₹1 L₹7 Cr₹7 Cr₹7 Cr₹7 Cr₹7 Cr₹7 Cr
₹87 L₹88 L₹65 L₹32 L₹2 Cr₹22 L₹22 L₹22 L₹22 L
₹0₹0₹0₹0₹0₹0₹0₹17,797₹10,636
₹75 Cr₹68 Cr₹83 Cr₹21 Cr₹23 Cr₹22 Cr₹23 Cr₹23 Cr₹23 Cr
₹36 Cr₹25 Cr₹16 Cr₹8 Cr₹5 Cr₹7 Cr₹5 Cr₹2 Cr₹3 Cr
₹14 Cr₹18 Cr₹9 Cr₹11 Cr₹8 Cr₹6 Cr₹10 Cr₹10 Cr₹10 Cr
₹56 Cr₹61 Cr₹15 Cr₹8 Cr₹1 Cr₹91 L₹3 Cr₹1 Cr₹63 L
₹2 Cr₹1 Cr₹1 Cr₹60 L₹1 Cr₹2 Cr₹2 Cr₹3 Cr₹1 Cr
₹74 Cr₹57 Cr₹8 Cr₹19 Cr₹21 Cr₹18 Cr₹8 Cr₹11 Cr₹11 Cr
₹181 Cr₹162 Cr₹49 Cr₹47 Cr₹36 Cr₹35 Cr₹29 Cr₹28 Cr₹26 Cr
₹137 Cr₹122 Cr₹19 Cr₹23 Cr₹17 Cr₹14 Cr₹12 Cr₹10 Cr₹9 Cr
₹256 Cr₹230 Cr₹132 Cr₹68 Cr₹59 Cr₹57 Cr₹52 Cr₹50 Cr₹49 Cr
₹8₹7₹5₹3₹3₹3₹3₹3₹2
₹8₹7₹5₹3₹3₹3₹3₹2₹2

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
₹21 Cr₹16 Cr₹6 Cr₹5 Cr₹5 Cr₹3 Cr₹3 Cr₹1 Cr₹3 Cr
-₹4 Cr₹2 Cr-₹39 L₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr
-₹25 Cr-₹65 Cr₹18 Cr₹5 Cr-₹7 Cr-₹6 Cr-₹3 Cr₹1 Cr-₹4 Cr
-₹8 Cr-₹47 Cr₹24 Cr₹13 Cr₹10 L-₹2 Cr₹2 Cr₹4 Cr₹59 L
-₹11 Cr-₹47 Cr₹24 Cr₹12 Cr-₹1 Cr-₹2 Cr₹2 Cr₹3 Cr-₹11 L
₹82 L₹19 Cr-₹38 Cr-₹2 Cr-₹2 L-₹22 L-₹99 L-₹67 L-₹97 L
₹5 Cr₹74 Cr₹21 Cr-₹2 Cr₹2 Cr-₹35 L₹1 Cr-₹2 Cr₹86 L
-₹5 Cr₹46 Cr₹6 Cr₹8 Cr₹16 L-₹2 Cr₹2 Cr₹39 L-₹22 L
₹61 Cr₹15 Cr₹9 Cr₹1 Cr₹91 L₹3 Cr₹1 Cr₹63 L₹85 L
₹56 Cr₹61 Cr₹15 Cr₹9 Cr₹1 Cr₹91 L₹3 Cr₹1 Cr₹63 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)11.75
Volume (₹)2.62 L
High (₹)12.38
Upper Circuit14.16
Low (₹)11.75
Lower Circuit9.44
Prev Close11.80
52W High (₹)17.25
Price12.00
52W Low (₹)7.05

Share Market Cap & Key Ratios Overview

M.Cap (₹)286.68 Cr
Div. Yield (%)0.00
PE Ratio14.78
Debt to Equity0.13
Price to Book1.51
Book Value7.96
EPS (TTM)0.80
Face Value1.00
ROE (%)10.49

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
CIPLA-ANSE
LAURUSLABS-ANSE
LUPIN-ANSE
MANKIND-ANSE
DRREDDY-ANSE
AUROPHARMA-ANSE
GENNEX-XNSE
LTP
1W Low
1W High
Market cap (₹)
1899.85-20.25 (-1.05%)
1896.30
1964.85
4,56,833Cr
9137-132 (-1.42%)
9051.85
9296
2,45,426Cr
4837.35-197.65 (-3.93%)
4822.25
5049
1,87,320Cr
1130.4-56.6 (-4.77%)
1126
1191.45
1,13,217Cr
1380.6-37.4 (-2.64%)
1376
1426.20
1,12,212Cr
1843.8-91.5 (-4.73%)
1812
1947.90
1,01,155Cr
2109.55-65.45 (-3.01%)
2107.35
2209
97,626Cr
2331.35-56.05 (-2.35%)
2323.15
2407.40
96,859Cr
1157-20.8 (-1.77%)
1155
1179.90
96,406Cr
1653.55+3.55 (0.22%)
1623.05
1706.70
93,614Cr
12-0.91 (-7.05%)
11.70
12.99
287Cr

Gennex Laboratories Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹6.38Cr; with other income of ₹2.01Cr, profit before interest and tax came to ₹5.82Cr. Interest expense was ₹90Lakh; PBT before exceptional items stood at ₹4.92Cr. Cost mix (full year): raw materials ₹100.59Cr; employee cost ₹8.35Cr; depreciation ₹56.9Lakh; other expenses ₹35.47Cr. Basis: consolidated annual results.

Gennex Laboratories Ltd Quaterly Results Key Takeaways

Gennex Laboratories Ltd reported ₹39.84Cr total income from operations in Jun 2026, softer than ₹60.95Cr in Mar 2026 but higher than ₹34.18Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹6.38Cr; with other income of ₹2.01Cr, profit before interest and tax came to ₹5.82Cr. Interest expense was ₹90Lakh, taking profit before tax to ₹4.92Cr. After tax of ₹25Lakh, profit after tax stood at ₹4.67Cr (vs ₹4.46Cr in Mar 2026 and ₹5.02Cr in Jun 2025).